Endocrine Complications of Checkpoint Inhibitors
What does the evidence show about recognizing and managing endocrine complications of checkpoint inhibitors, and how well does it establish their frequency and course?
Following this dossier shows how clinical guidance on these complications develops as reviews and case reports add evidence. It helps readers distinguish practical recommendations from conclusions supported by broader patient data.
Where it stands now
Main bottleneck
Current evidence contains clinical reviews and a planned case report, but no larger patient dataset is listed. That leaves the frequency, course, and comparative outcomes of different management approaches unresolved in this trajectory.
Watch next
Watch for a larger clinical study with patient denominators and follow-up that reports how often these complications occur and how they progress under different management approaches.
Progress timeline
How the evidence has changed over time.
2025 · 1 update
- Thyroid treatment preceded an adrenal crisis after cancer immunotherapySource date 2025-11-21
Since the previous research note · Earlier expectation not tested
Track continuity
Since the previous research note: Which hormone problems can arise during cancer immunotherapy?
Previous expectation: More coordinated recognition and management of hormone complications might reduce acute harm for people receiving checkpoint inhibitors.
What this study adds: This 2025 patient-level case adds a specific sequence of thyroid replacement, adrenal crisis and improvement after prednisone amid competing explanations for adrenal insufficiency. It did not evaluate a coordinated safety program.
Current research note
2022 · 1 update
- Which hormone problems can arise during cancer immunotherapy?Source date 2022-04-25
Since the previous research note · Earlier expectation not tested
Track continuity
Since the previous research note: Why cancer immunotherapy can affect the thyroid and pituitary in ways that are hard to recognize
Previous expectation: Timely hormone care might prevent harm and allow some patients to continue checkpoint treatment.
What this study adds: The 2022 review broadens the clinical map beyond thyroid and pituitary effects, distinguishes patterns by checkpoint target, and discusses diagnosis and management across specialties.
Current research note
2021 · 1 update
How this Track works
This page changes as new evidence arrives. Open any update to see what researchers found at that point in the story.